AudioScholar Rheumatology Weekly (India)

AudioScholar
  • 0.0 (0)
  • Medicine
  • Weekly

A weekly podcast briefing of the most significant peer-reviewed rheumatology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc. India edition.

  1. 1h ago

    Tirzepatide plus ixekizumab lifts ACR50 in PsA: exploratory

    Editor's Pick: Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial (Arthritis & Rheumatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. This week: a weight-loss drug added to an IL-17 inhibitor keeps improving psoriatic arthritis at one year, new international treatment guidelines arrive for IgG4-related disease, and a type two anti-CD20 antibody beats placebo in active lupus. This week's papers: 1. Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Ove…. Arthritis & Rheumatology 2026. 2. The IgG4ward! Foundation guidelines on the treatment of IgG4-related disease.. Lancet Rheumatology 2026. 3. Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase…. Lancet Rheumatology 2026. 4. Longitudinal trends in vaccination uptake and respiratory infection burden in systemic lupus erythematosus: a population-based cohort study.. Rheumatology 2026. 5. Biomarker trajectories and risk of relapse in giant cell arteritis: a multicenter study.. Seminars in Arthritis and Rheumatism 2026. 6. Predicting Inactive Disease in Juvenile Idiopathic Arthritis: A Dynamic Machine Learning Approach.. Arthritis & Rheumatology 2026. 7. Enhancing Return to Daily Life Activities after Total and Unicompartmental Knee Arthroplasty with a Personalized eHealth Program - Results of the Multicentre A…. Osteoarthritis and Cartilage 2026. 8. Blinatumomab in dermatomyositis and refractory ANCA-associated vasculitis: a 2-patient exploratory study.. Annals of the Rheumatic Diseases 2026. 9. Anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome: Clinical associations and methodological heterogeneity-a scoping review.. Seminars in Arthritis and Rheumatism 2026. 10. Immune checkpoint inhibitor-associated inflammatory arthritis.. Nature Reviews Rheumatology 2026. Listen at https://audioscholar.cc/episode/d48c7msdut

  2. 6d ago

    App-led treat-to-target gout care: 85% at urate target

    Editor's Pick: Effects of a Smartphone-Enabled, Physician-Supervised Treat-to-Target Model for Gout Management: A 12-Month Randomized Controlled Trial (Arthritis & Rheumatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning the fibrosing diseases from skin to kidney, lupus treatment response, and the infection and mortality burden that shadows our immunomodulatory therapies, with a… This week's papers: 1. Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study.. Annals of the Rheumatic Diseases 2026. 2. Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study.. Lancet Rheumatology 2026. 3. Treatment patterns and outcomes of scleroderma renal crisis in the international scleroderma renal crisis survey II - An inception cohort study.. Seminars in Arthritis and Rheumatism 2026. 4. Effect of ethnicity on response to treatment escalation in patients with systemic lupus erythematosus from the British Isles Lupus Assessment Group Biologics R…. Lancet Rheumatology 2026. 5. Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study.. Lupus Science & Medicine 2026. 6. Combination advanced therapy use and infection risks in immune-mediated inflammatory diseases.. Rheumatology 2026. 7. All-cause and cause-specific mortality in people with rare autoimmune rheumatic diseases in England using whole population data.. Rheumatology 2026. 8. Practical recommendations for revaccination following BCMA-targeted therapies in adult patients with autoimmune diseases.. Annals of the Rheumatic Diseases 2026. 9. Effects of a Smartphone-Enabled, Physician-Supervised Treat-to-Target Model for Gout Management: A 12-Month Randomized Controlled Trial.. Arthritis & Rheumatology 2026. 10. The impact of HFE genotypes and iron loading on joint disease: evidence for HFE-associated arthropathy without genetic haemochromatosis.. Annals of the Rheumatic Diseases 2026. Listen at https://audioscholar.cc/episode/tgegq5bhfa

  3. Oct 29

    Rituximab no better than azathioprine for EGPA maintenance

    Editor's Pick: Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial (JAMA, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning B-cell targeted therapy in two difficult systemic diseases, interstitial lung disease across the connective tissue diseases, and real-world comparisons of targe… This week's papers: 1. Ianalumab for the Treatment of Patients with Sjögren's Disease.. New England Journal of Medicine 2026. 2. Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial.. JAMA 2026. 3. Real-world association of biologic and targeted synthetic DMARD use with mortality in rheumatoid arthritis-associated interstitial lung disease: a nationwide c…. RMD Open 2026. 4. Survival and immunomodulatory therapy in autoimmune disease-associated progressive pulmonary fibrosis: a multicenter registry (NEREA).. Rheumatology 2026. 5. Predictors of response and long-term efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study.. Seminars in Arthritis and Rheumatism 2026. 6. Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort.. Rheumatology 2026. 7. Real‑world assessment of the effectiveness and response profiles of biologic DMARDs in psoriatic arthritis: findings from an emulated multicentre clinical tria…. Annals of the Rheumatic Diseases 2026. 8. International recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica.. Annals of the Rheumatic Diseases 2026. 9. Extra-renal disease patterns in lupus nephritis: clinical and serological activity confers increased risk of renal flares and damage accrual.. Rheumatology 2026. 10. First trimester exposure to hydroxychloroquine during pregnancy and major congenital malformations: a systematic review and meta-analysis.. RMD Open 2026. Listen at https://audioscholar.cc/episode/c5a7y5e3ff

  4. Oct 22

    Early treat-to-target RA: 82% in remission at 10 years

    Editor's Pick: Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis (Annals of the Rheumatic Diseases, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning long-term strategy and drug sequencing in rheumatoid arthritis, new data and new standards in psoriatic arthritis, axial spondyloarthritis and osteoarthritis, a… This week's papers: 1. Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis.. Annals of the Rheumatic Diseases 2026. 2. Cardiovascular risk associated with first-line Janus kinase inhibitors versus TNF inhibitors in patients with RA: a nationwide cohort study.. Rheumatology 2026. 3. Reasons-stratified treatment retention after JAK inhibitor discontinuation in rheumatoid arthritis: the ANSWER cohort study.. Rheumatology 2026. 4. Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies.. Lancet Rheumatology 2026. 5. Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic-Naïve Participants with Active and Erosi…. Arthritis & Rheumatology 2026. 6. The ASAS core set for the assessment of axial spondyloarthritis in clinical practice.. Annals of the Rheumatic Diseases 2026. 7. Emerging therapies for knee osteoarthritis.. Nature Reviews Rheumatology 2026. 8. Deep clinical renal response in lupus nephritis treated with belimumab: a real-world cohort study.. Rheumatology 2026. 9. Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis-associated pulmonary arterial h…. Arthritis & Rheumatology 2026. 10. Clinical performance of obstetric antiphospholipid syndrome classification criteria: an ambispective cohort study.. Rheumatology 2026. Listen at https://audioscholar.cc/episode/4wc7uuj3d9

  5. Oct 15

    Polymyalgia guideline: faster taper, early methotrexate

    Editor's Pick: The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica (Rheumatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning a refreshed approach to polymyalgia rheumatica, the evolving biologic toolkit in lupus and psoriatic arthritis, and the hidden risks that travel with rheumatic… This week's papers: 1. The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica.. Rheumatology 2026. 2. Imaging for diagnosis, monitoring and outcome prediction in polymyalgia rheumatica: a systematic literature review and meta-analysis informing an international…. RMD Open 2026. 3. Long-term comparative outcomes of rituximab and belimumab in lupus patients.. Rheumatology 2026. 4. B-cell landscape remodelling following dual BAFF/APRIL inhibition with telitacicept in lupus nephritis: extrafollicular axis clearance and its association with…. Lupus Science & Medicine 2026. 5. Antimalarial exposure and renal histopathologic findings in lupus nephritis.. Rheumatology 2026. 6. Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies.. Rheumatology 2026. 7. Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.. Arthritis & Rheumatology 2026. 8. Cardiovascular risk stratification using chest CT in idiopathic inflammatory myopathies.. Rheumatology 2026. 9. IgG4-related disease is not associated with an increased incidence of malignancy in a large, single-centre cohort.. Annals of the Rheumatic Diseases 2026. 10. Genomic ascertainment of systemic autoinflammatory diseases: a retrospective cohort study in two population-based biobanks.. Lancet Rheumatology 2026. Listen at https://audioscholar.cc/episode/yj7dmq7nf3

  6. Oct 8

    Holding DMARDs post-booster: no antibody gain, more flares

    Editor's Pick: Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis: The COVER Randomized Clinical Trial (JAMA Internal Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning when and how to step back from targeted therapy in inflammatory arthritis, the long shadow of glucocorticoids in lupus and polymyalgia, and the emerging framewo… This week's papers: 1. Outcomes of Tapering Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: A Multicenter Randomized Non-Inferiority Trial.. Arthritis & Rheumatology 2026. 2. Comparative efficacy and safety of disease-modifying antirheumatic drugs tapering strategies in sustained-remission rheumatoid arthritis: Systematic review and…. Seminars in Arthritis and Rheumatism 2026. 3. Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis: The COVER Randomized Clinic…. JAMA Internal Medicine 2026. 4. Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review.. Annals of the Rheumatic Diseases 2026. 5. Impact of bimekizumab on CANDEN spinal MRI inflammation & structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 results.. Rheumatology 2026. 6. Oral glucocorticoid dose patterns and organ damage in systemic lupus erythematosus - a nationwide cohort study.. Arthritis & Rheumatology 2026. 7. Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies.. Lupus Science & Medicine 2026. 8. Study on the implementation of the 2015 EULAR/ACR recommendations for polymyalgia rheumatica in clinical practice.. RMD Open 2026. 9. CAR T cells for autoimmune diseases: 2026 update of the EBMT-ISCT-JACIE practice harmonisation and consensus recommendations.. Lancet Rheumatology 2026. 10. Immune reset in rheumatic autoimmune disease: from a tantalising metaphor to a measurable therapeutic state.. Annals of the Rheumatic Diseases 2026. Listen at https://audioscholar.cc/episode/h37d5f4nht

  7. Oct 1

    PH in anti-synthetase syndrome tied to higher mortality

    Editor's Pick: Pulmonary hypertension in anti-synthetase syndrome: prevalence, comparative risk across autoimmune diseases, and impact on survival (Rheumatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning lupus treatment and prognosis, risk prediction across vasculitis, giant cell arteritis and gout, and treatment strategy questions in rheumatoid arthritis, juven… This week's papers: 1. Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythema…. RMD Open 2026. 2. Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer:…. RMD Open 2026. 3. Predicting relapse and infection to optimize patient outcomes in ANCA-associated vasculitis: data from the MAINRITSAN trials cohort.. Rheumatology 2026. 4. Overall and specific treatment effects of pharmacological interventions for hand osteoarthritis: a systematic review and meta-analysis of randomized controlled…. Osteoarthritis and Cartilage 2026. 5. Comparison of four clinical risk prediction models for the diagnosis of giant cell arteritis: results from the ongoing PREDICT-GCA study.. RMD Open 2026. 6. Ability of SLE-DAS and SLEDAI-2K to predict damage accrual in SLE: A real-world 7-year cohort study from Sweden.. Rheumatology 2026. 7. Management strategies for articular flares during biologic therapy in non-systemic polyarticular JIA: a multicentre study.. Rheumatology 2026. 8. Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a tria…. Lancet Rheumatology 2026. 9. Pulmonary hypertension in anti-synthetase syndrome: prevalence, comparative risk across autoimmune diseases, and impact on survival.. Rheumatology 2026. 10. DNA methylation signatures distinguish gout from asymptomatic hyperuricaemia and converge with genetic risk at immune-metabolic loci.. Annals of the Rheumatic Diseases 2026. Listen at https://audioscholar.cc/episode/dyjrs3gv76

  8. Sep 24

    Golimumab: ~half without psoriasis drug-free at 10 years

    Editor's Pick: Drug-Free Remission in Early Peripheral Spondyloarthritis, including Psoriatic Arthritis: 10-year follow-up from the CRESPA trial (Arthritis & Rheumatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning vasculitis risk stratification and early biologic therapy, the steroid-sparing treat-to-target agenda in lupus, and remission, tapering and refractory disease i… This week's papers: 1. Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial.. Annals of the Rheumatic Diseases 2026. 2. Diagnostic accuracy of musculoskeletal ultrasound in suspected polymyalgia rheumatica: a multicentre, cohort study.. Lancet Rheumatology 2026. 3. Early mepolizumab initiation during remission induction is associated with lower organ damage burden in EGPA: a multicentre cohort study.. Rheumatology 2026. 4. Evaluating a guideline-aligned prednisone threshold within the Lupus Low Disease Activity State (LLDAS): associations with damage accrual.. RMD Open 2026. 5. Treat-to-target: LLDAS, DORIS remission, and flare prevention strategies.. Rheumatology 2026. 6. Drug-Free Remission in Early Peripheral Spondyloarthritis, including Psoriatic Arthritis: 10-year follow-up from the CRESPA trial.. Arthritis & Rheumatology 2026. 7. Relevance of the 2025 ESC guidelines for the diagnosis and management of myocarditis and pericarditis for systemic autoimmune rheumatic diseases.. Lancet Rheumatology 2026. 8. Integrated serum proteomics and autoantibody analyses reveal a biomarker signature predictive of flare during biologic tapering in rheumatoid arthritis.. RMD Open 2026. 9. Association between initial treatment strategy and progression to difficult-to-treat rheumatoid arthritis (D2T-RA): evidence from a 20-year-old real-world coho…. RMD Open 2026. 10. Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure.. RMD Open 2026. Listen at https://audioscholar.cc/episode/5ngs6ep2cw

See All (27)

About

A weekly podcast briefing of the most significant peer-reviewed rheumatology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc. India edition.

Information